Clone:
REAL1146
Type of antibody:
Releasable fluorochromes, Primary antibodies, Recombinant antibodies
Applications:
MICS, IHC, IF
Alternative names:
Basement-membrane protein 40, BM-40, Osteonectin, ON, Secreted protein acidic and rich in cysteine

Specifications for SPARC Antibody, anti-human, REAdye_lease™

Overview

Clone REAL1146 is an antibody fragment derived from the full SPARC antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity.
Clone REAL1146 recognizes SPARC, a 43kDa cysteine-rich acidic matrix-associated protein, which is also known as Osteonectin and ON. It is mainly detected in the extracellular compartment. SPARC has different functions. It plays a role in cell differentiation, proliferation and angiogenesis and is involved in tissue remodeling and wound repair. Expression of SPARC is detected in different tissues and organs and has been associated with tumor suppression. A strong expression is found in tissues undergoing morphogenesis and wound repair.
For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675).

Alternative names

Basement-membrane protein 40, BM-40, Osteonectin, ON, Secreted protein acidic and rich in cysteine

Detailed product information

Technical specifications

CloneREAL1146
Clonalitymonoclonal
Isotype controlControl Antibody
Hosthuman cell line
Type of antibodyReleasable fluorochromes, Primary antibodies, Recombinant antibodies
Specieshuman
AntigenSPARC
Alternative names of antigenBasement-membrane protein 40, BM-40, Osteonectin, ON, Secreted protein acidic and rich in cysteine

Resources for SPARC Antibody, anti-human, REAdye_lease™

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for SPARC Antibody, anti-human, REAdye_lease™

Publications

  1. Feng, J. et al. (2014) SPARC in Tumor Pathophysiology and as a Potential Therapeutic Target. Curr. Pharm. Des. 20(39): 6182-6190
  2. Rosset, E. M. and Bradshaw, A. D. et al. (2016) SPARC/osteonectin in mineralized tissue. Matrix Biol. 52(54): 78-87

Related products for
SPARC Antibody, anti-human, REAdye_lease™

1 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?